Tel.: +33-472738402, Fax: +33-472738345
1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
Mini Review
Eurogin 2010 roadmap on cervical cancer prevention†
Article first published online: 25 MAR 2011
DOI: 10.1002/ijc.25915
Copyright © 2011 UICC
Additional Information
How to Cite
Franceschi, S., Denny, L., Irwin, K. L., Jeronimo, J., Lopalco, P. L., Monsonego, J., Peto, J., Ronco, G., Sasieni, P. and Wheeler, C. M. (2011), Eurogin 2010 roadmap on cervical cancer prevention. Int. J. Cancer, 128: 2765–2774. doi: 10.1002/ijc.25915
- †
Conflicts of interest: Prof. L. Denny has received honoraria for appearing on various speaker fora for Merck and GSK and is currently conducting a randomized trial of the safety and immunogenicity of the bivalent vaccine sponsored by GSK. Dr. J. Monsonego has received funding to conduct studies related to the FASE study from Gen-Probe Inc. and related to HPV vaccines from Merck and GSK and has participated in Steering Committees at Merck and in the Advisory Board of Sanofi Pasteur MSD and Roche Diagnostics. Prof. J. Peto and Prof. P. Sasieni were invited by GSK to attend the IPC conference in Montreal in 2010. Prof. P. Sasieni received payment for participating in an advisory meeting for Gen-Probe Inc. as well as minor payment from Qiagen in 2010. The work reported in this manuscript was undertaken while Prof J. Peto was recipient of a Senior Visiting Scientist Award granted by the International Agency for Research on Cancer. Dr. G. Ronco received minor payment for participating in advisory boards for Gen-Probe Inc. in 2007 and 2008. Dr. C. Wheeler has received funding through her institution for equipment and reagents for HPV genotyping from Roche Molecular Systems and to conduct studies related to HPV vaccines from Merck and GSK
Publication History
- Issue published online: 22 APR 2011
- Article first published online: 25 MAR 2011
- Accepted manuscript online: 4 JAN 2011 10:33AM EST
- Manuscript Accepted: 20 DEC 2010
- Manuscript Received: 14 OCT 2010
Funded by
- Bill & Melinda Gates Foundation, USA. Grant Number: 35537
- Abstract
- Article
- References
- Cited By
Keywords:
- cervical cancer;
- human papillomavirus;
- screening;
- vaccination
Abstract
The EUROGIN 2010 roadmap represents a continuing effort to provide and interpret updated information on cervical cancer screening and vaccination against the cause of the disease, high-risk human papillomavirus (HPV). Contrary to the two previous reports in 2008 and 2009, the present roadmap gives equal room to HPV-based screening and HPV vaccination, as a result of the recent strengthening of the evidence on the efficacy and feasibility of both approaches. The superiority of HPV testing in primary screening compared to cytology (in more developed countries) and to cytology or visual inspection methods (in less developed countries) has been demonstrated in several randomised trials. High vaccine efficacy has been confirmed up to 7 years after vaccination; school-based programmes in some countries have been able to reach over 70% coverage among adolescent girls. Demonstration projects have indicated that the delivery of HPV vaccines in less developed countries is feasible and favourably received by populations where cervical cancer is very common. HPV-based screening can diminish cervical cancer incidence more quickly than HPV vaccination, but vaccination can eventually facilitate screening efforts, especially if new vaccines against a greater number of HPV types are introduced. The availability of two highly complementary prevention tools such as HPV testing and HPV vaccination makes it possible to conceive integrated strategies for the elimination of cervical cancer that have no precedent in the cancer field. HPV tests and HPV vaccines remain, however, too expensive, and large-scale financing of screening and vaccination in less developed countries is sorely lacking.